Title: High-Sensitivity C-Reactive Protein in Systemic Lupus Erythematosus Patients without Cardiac Involvement: Relation to Disease Activity and Intima-Media Thickness
Authors: Mona H. EL Zohri, Mohamed A. Tohammy, Ahmed A.Obiedallah, Effat AE Tony, Huda M Kamel, Mohamed Z Abd Elrhman
DOI: https://dx.doi.org/10.18535/jmscr/v5i3.78
Abstract
Objectives: measuring hs-CRP in SLE patients without clinical cardiac involvement and finds its relation to disease activity and carotid intima media thickness (CIMT), to detect a possible subclinical atherosclerosis.
Methods: 40 SLE patients without cardiac involvement and 20 controls. Disease activity was evaluated using SLEDAI. A SLEDAI of 6 or more is consistent with active disease. CIMT increased if > 0.7 mm.
Results: hs-CRP in SLE patients was significantly higher than controls. 29 patients had high risk level of hs-CRP(> 3 mg/L) , 5 patients had average risk (1-3mg/L) , 6 patients had a low risk ( < 1 mg/L ) compared to the controls. Hs-CRP was significantly higher in patients with positive antids DNA compared to those with negative results, (P 0.003, r 0.5). Hs-CRP significantly correlated with SLEDAI, (P 0.001, r 0.49). CIMT in SLE patients was significantly increased (0.81± 0.42 mm), (>7 mm) compared to controls (0.54± 0.15 mm). 90% of SLE patients with increased CIMT have high risk hs-CRP, 10% of SLE patients with increased CIMT have averege risk hs-CRP compared to those at lower levels (0 %), while 55% of SLE patients with normal CIMT have high risk hs-CRP, 15% of SLE patients with normal CIMT have averege risk hs-CRP, 30% of SLE patients with normal CIMT have a low risk hs-CRP. A significant correlation between hs-CRP and CIMT (p 0.019, and r 0.39).
Conclusion: hs-CRP may be a useful marker of disease activity and increased CIMT in SLE.
Keywords: Systemic lupus erythematosus-High-sensitivity C-reactive protein- Carotid Intima Media Thickness- Subclinical atherosclerosis.
References
1. 1. Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrøm K et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 2014;73:958-67.
2. M B Urowitz, D, D Gladman, N M Anderson, J Su, J Romero-Diaz, S C Bae et al. Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort. Lupus Sci Med 2016;12:e000143.
3. Nermeen Khairy, Yasser Ezzat, Nahla Naeem, Radwa Taha, Rasha Wesam. Atherosclerosis biomarkers in female systemic lupus erythematosus patients with and without cardiovascular diseases. The Egyptian Rheumatologist http://dx.doi.org/10.1016/j.ejr.2016.03.003
4. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340:448–54.
5. Gaitonde S, Samols D, Kushner I. C-reactive protein and systemic lupus erythematosus. Arthritis Rheum 2008;59: 1814–20.
6. Qureshi WT, Rana JS, Yeboah J, Bin Nasir U, Al-Mallah MH. Risk stratification for primary prevention of coronary artery disease: roles of C-reactive protein and coronary artery calcium. Curr Cardiol Rep 2015;17:110.
7. David C. Goff Jr, Donald M. Lloyd-Jones, Glen Bennett, Sean Coady, D'Agostino RB, Gibbons R et al. ACC/AHA guideline on the assessment of cardiovascular risk : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129:49-73.
8. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557–65.
9. Bertoli AM, Vilá LM, Reveille JD, Alarcón GS, LUMINA Study Group Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): LXI. Value of C-reactive protein as a marker of disease activity and damage. J Rheumatol 2008;35:2355–8.
10. Barnes EV, Narain S, Naranjo A, Shuster J, Segal MS, Sobel ES et al. High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implicat-ions for cardiovascular risk. Lupus 2005; 14:576–82.
11. Lee SS, Singh S, Magder LS, Petri M. Predictors of high sensitivity C-reactive protein levels in patients with systemic lupus erythematosus. Lupus 2008;17:114–23.
12. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132–40.
13. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002; 105:1760-3.
14. Mok CC, Tang SSK, ToC H, Petri MA. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum 2005;52: 2774–82.
15. Bauer M, Möhlenkamp S, Lehmann S, Schmermund A, Roggenbuck U, Moebus S, et al. The effect of age and risk factors on coronary and carotid artery atherosclerotic burden in males—results of the Heinz Nixdorf Recall Study. Atherosclerosis. 2009;205:595–602.
16. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
17. Bombardier, C., Gladman, D.D. and Urowitz, M.B. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
18. Gladman, D.D., Ibanez, D. and Urowitz, M.B. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-91.
19. Bertsias G, Ioannidis JP, Boletis J et al. European League against Rheumatism (EULAR) recommendations for the management of systemic lupu erythemat-osus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2008;67:195-205.
20. Lipson A, Alexopoulos N, Hartlage GR, Arepalli C, Oeser A, Bian A et al. Epicardial adipose tissue is increased in patients with systemic lupus erythema-tosus. Atherosclerosis 2012;223: 389–93.
21. C.S. He, W. Shi, Z.M. Ye, X.L. Liang, B. Zhang, S.X. Liu. Cardiovascular risk profile in systemic lupus erythematosus: a cross sectional study of 879 patients. Nan Fang Yi Ke Da Xue Xue Bao. 2011;31:1910–3.
22. O’Neill SG, Isenberg DA, Rahman A. Could antibodies to C-reactive protein link inflammation and cardiovascular disease in patients with systemic lupus erythem-atosus? Ann Rheum Dis 2007;66:989–91.
23. De Leeuw K, Freire B, Smit AJ, Bootsma H, Kallenberg CG, Bijl M. Traditional and non-traditional risk factors contribute to the development of accelerated atheroscl-erosis in patients with systemic lupus erythematosus. Lupus 2006;15:675–82.
24. Rezaieyazdi Z, Sahebari M, Hatef MR, Abbasi B, Rafatpanah H, Afshari JT, et al. Is there any correlation between high sensitive CRP and disease activity in systemic lupus erythematosus? Lupus 2011;20:1494–500.
25. Tincani A, Rebaioli CB, Taglietti M, Shoenfeld Y. Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus. Rheumatology (Oxford) 2006;45:8–13.
26. D'Cruz D, Khamashta M, Hughes GRV. Cardiovascular manifestations of systemic lupus erythematosus. In: Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. Philadelphia: 2001. p. 645.
27. Ter Borg EJ, Horst G, Limburg PC, van Rijswijk MH, Kallenberg CG. C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: a prospective longitudinal study. J Rheumatol 1990;17:1642–8.
28. Williams Jr RC, Harmon ME, Burlingame R, Du Clos TW. Studies of serum C-reactive protein in systemic lupus erythe-matosus. J Rheumatol 2005;32:454–61.
29. Spronk PE, ter Borg EJ, Kallenberg CG. Patients with systemic lupus erythematosus and Jaccound’s arthropathy: a clinical subset with an increased C reactive protein response? Ann Rheum Dis 1992;51:358–61.
30. Keenan RT, Swearingen CJ, Yazici Y. Erythrocyte sedimentation rate and C-reactive protein levels are poorly correlated with clinical measures of disease activity in rheumatoid arthritis, systemic lupus erythematosus and osteoarthritis patients. Clin Exp Rheumatol 2008;26:814–9.
31. Sjo¨ wall C, Bengtsson AA, Sturfelt G, Skogh T. Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus. Arthritis Res Ther 2004; 6:87–94.
32. Gheita T, Yasser Y, Gamal S, Hussein H. C-reactive protein and asymptomatic pericardial effusion in patients with systemic lupus erythematosus. Egypt. Rheumatologist 2009;31:1–16.
33. Panafidina TA, Popkova TV, Alekberova ZS, Novikova PS, Mach ES, Aleksandrova EN, et al. The significance of cardiovascular risk factors and C-reactive protein to the development of atherosclerosis in women with systemic lupus erythematosus. Klin Med (Mosk) 2006;84:49–54.
34. Tamer A, Gheita, Iman I, El-Gazzar, Ghada Azkalany, Hussein. El-Fishawy, High-sensitivity C-reactive protein (hs-CRP) in systemic lupus erythematosus patients without cardiac involvement; relation to disease activity, damage and intima-media thickness. The Egyptian Rheumatologist 2012;34,147–52.
35. Kiani AN, Fishman EK, Petri M. Aortic valve calcification in systemic lupus erythematosus. Lupus 2006;15:873–6.
36. Wettero J, Nilsson L, Jonasson L, Sjöwall C. Reduced serum levels of autoantibodies against monomeric C-reactive protein (CRP) in patients with acute coronary syndrome. Clin Chim Acta 2009;400:128–31.
37. Sjöwall C, Bengtsson T, Skogh T. CRP and anti-CRP autoantibodies in systemic lupus erythematosus. Curr Rheumatol Rev 2005;181:89.
38. Mok CC, Birmingham DJ, Ho LY, Hebert LA, Rovin BH. High sensitivity C-reactive protein, disease activity and cardiovascular risk factors in systemic lupus erythematosus. Arthritis Care Res 2013;65:441–47.
39. Anania C, Gustafsson T, Hua X, Su J, Vikstrom M, de Faire U et al. Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosus. Arthritis Res Ther 2010;12:R214.
40. Sherer Y, Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2006;2:99–106.